NCT07030569View on ClinicalTrials.gov

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions
RadiomicRadiomicsBreast Cancer MetastaticBreast Cancer Stage IVBreast CarcinomaBreast NeoplasmsBreast CancerBreast Cancer With Bone MetastasisBreast Cancer With Metastatic Bone DiseaseTrastuzumabHER2HER2 + Breast CancerHER2 Positive Breast CarcinomaHER2-positive Breast CancerHer2/Neu Positive Advanced Solid TumorsHER2/Neu-positive Breast Cancer
Interventions
DRUG

Trastuzumab deruxtecan (DS-8201a)

A subgroup of the study cohort treated with Trastuzumab Deruxtecan in the metastatic setting

Trial Locations (1)

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale Tumori, Milan

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER